Segment 1: Considering the Value of Diagnostic Tests

Panel moderator Surabhi Dangi-Garimella, PhD, managing editor of AJMC’s Evidence-Based series, starts the panel discussion with a discussion about how payers and physicians evaluate the value of a particular diagnostic test.

The problem with new genomic next-generation sequencing clinical studies is that use in the last few years is not based on clinical or outcomes, Francisco J. Esteva, MD, PhD, said.

“Outcomes in a particular relevant patient population used to be and it should be our most factor, but I’m not sure that’s what’s happening today,” he said.